Exhibit 99.1 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Condensed Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022 | 2 | | Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months | | | Ended Sept ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Dr. Christian Itin - CEO Dr. Lucinda Crabtree - CFO Rob Dolski - incoming CFO Julia Wilson - IR Conference Call Participants Matt Phipps - William Blair Asthika Goonewardene - Truist Financial Kelly Shi - Jefferies Noah Burhance - J.P. Morgan Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Second Quarter 2023 Financial Results Conference. At this time, all part ...

Second Quarter Financial Results and Operational Progress ...

Exhibit 99.1 | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | | | Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022 | 2 | | Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2023 and 2022 (Una ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Alexandra Deschner - IR, Consultant Christian Itin - CEO Lucinda Crabtree - CFO Conference Call Participants Mara Goldstein - Mizuho Group Matthew Phipps - William Blair Yanan Zhu - Wells Fargo Securities Gil Blum - Needham & Co. Kelly Shi - Jefferies Asthika Goonewardene - Truist Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics First Quarter 2023 Financial Results ...

First Quarter Financial Results and Operational Progress May 4, 2023 2 Developing Next Generation Programmed T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements i ...

[Condensed Consolidated Financial Statements](index=1&type=section&id=Condensed%20Consolidated%20Financial%20Statements) [Condensed Consolidated Balance Sheets](index=2&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $460.0 million by March 31, 2023, from $490.3 million, primarily due to reduced cash and a decline in equity Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $343,027 | $382,436 | | Total current assets | $393,885 | $425,771 | | Total assets | $459,971 | $490,274 | | **Liabilities & Equity** | | | | Total current liabilities | $39,637 | $46,366 | | Total liabilities | $193,051 | $191,600 | | Total shareholders' equity | $266,920 | $298,674 | | Total liabilities and shareholders' equity | $459,971 | $490,274 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=3&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss increased to $39.8 million for Q1 2023 from $37.1 million in Q1 2022, despite new license revenue, driven by higher operating expenses Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | License revenue | $1,292 | $0 | | Total operating expenses, net | ($43,104) | ($41,784) | | Net loss | ($39,811) | ($37,062) | | Total comprehensive loss | ($34,170) | ($44,517) | | Basic and diluted net loss per ordinary share | ($0.23) | ($0.41) | [Condensed Consolidated Statements of Shareholders' Equity](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Shareholders'%20Equity) Shareholders' equity decreased from $298.7 million to $266.9 million by March 31, 2023, primarily due to the $39.8 million net loss Changes in Shareholders' Equity for Q1 2023 (in thousands) | Description | Amount | | :--- | :--- | | Balance at December 31, 2022 | $298,674 | | Share-based compensation expense | $2,416 | | Unrealized gain on foreign currency translation | $5,641 | | Net loss | ($39,811) | | **Balance at March 31, 2023** | **$266,920** | [Condensed Consolidated Statements of Cash Flows](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to $42.4 million in Q1 2023, leading to a $39.4 million decrease in total cash and equivalents Cash Flow Summary (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($42,419) | ($35,030) | | Net cash used in investing activities | ($3,622) | ($771) | | Net cash used in financing activities | ($691) | ($1) | | Net decrease in cash, cash equivalents and restricted cash | ($39,406) | ($41,784) | | Cash, cash equivalents and restricted cash, end of period | $343,355 | $268,892 | [Notes to Condensed Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) [Note 1. Nature of the Business](index=6&type=section&id=Note%201.%20Nature%20of%20the%20Business) Autolus Therapeutics, a clinical-stage biopharmaceutical company, continues to incur losses but maintains sufficient cash to fund operations for at least twelve months - The company is a biopharmaceutical firm developing next-generation programmed T cell therapies for cancer treatment[16](index=16&type=chunk) - The company has incurred recurring losses since inception, with a **net loss of $39.8 million** for the three months ended March 31, 2023, and an **accumulated deficit of $710.0 million**[16](index=16&type=chunk) - Management expects that its forecast cash will be **sufficient to fund operations for at least twelve months** from the issuance date of the financial statements[16](index=16&type=chunk) [Note 3. License Revenue](index=7&type=section&id=Note%203.%20License%20Revenue) The company recognized **$1.29 million in license revenue** in Q1 2023 from a new agreement with Cabaletta Bio Inc. for RQR8 safety switch technology - On January 9, 2023, the Company entered into an Option and License Agreement with Cabaletta Bio Inc., granting a non-exclusive license for its RQR8 safety switch technology[24](index=24&type=chunk) - The company recognized total **license revenue of $1.2 million** for the three months ended March 31, 2023, related to the Cabaletta Agreement, as the performance obligation was satisfied upon delivery of the license and know-how[24](index=24&type=chunk) [Note 7. Shareholders' Equity](index=10&type=section&id=Note%207.%20Shareholders'%20Equity) In December 2022, the company completed a public offering of **81.9 million ADSs** at $2.00 per ADS, raising **net proceeds of $152.4 million** - In December 2022, the Company completed an underwritten public offering of **81,927,012 ADSs** at a price of **$2.00 per ADS**, raising **net proceeds of $152.4 million** after underwriting discounts and offering expenses[35](index=35&type=chunk) [Note 9. Net loss per share](index=10&type=section&id=Note%209.%20Net%20loss%20per%20share) Basic and diluted net loss per share improved to **$0.23** in Q1 2023 from **$0.41** in Q1 2022, driven by a significant increase in outstanding shares Net Loss Per Share Calculation (in thousands, except share and per share data) | Description | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Net loss attributable to ordinary shareholders | ($39,811) | ($37,062) | | Weighted-average number of ordinary shares | 173,825,825 | 90,914,175 | | **Net loss per share - basic and diluted** | **($0.23)** | **($0.41)** | - Potentially dilutive securities, including **13.1 million share options** and **3.3 million warrants**, were excluded from the calculation as their effect would be anti-dilutive[41](index=41&type=chunk) [Note 10. Liability related to future royalties and sales milestones, net](index=11&type=section&id=Note%2010.%20Liability%20related%20to%20future%20royalties%20and%20sales%20milestones,%20net) The liability for future royalties and sales milestones, stemming from a Blackstone agreement, increased from **$125.9 million** to **$130.8 million** by March 31, 2023, due to non-cash interest expense - The liability is related to a strategic collaboration agreement with Blackstone from November 2021, involving future royalties and sales milestones[42](index=42&type=chunk) Activity in Liability for Future Royalties (in thousands) | Description | Amount | | :--- | :--- | | Balance at December 31, 2022 | $125,900 | | Non-cash interest expense | $4,905 | | **Balance at March 31, 2023** | **$130,805** | [Note 11. Leases](index=12&type=section&id=Note%2011.%20Leases) Total lease costs for Q1 2023 decreased to **$1.1 million** from **$1.4 million**, while the weighted-average remaining lease term significantly increased to **11.9 years**, reflecting new facility agreements Lease Information (in thousands, except years and percentage) | Metric | March 31, 2023 | March 31, 2022 | | :--- | :--- | :--- | | Total lease costs | $1,121 | $1,430 | | Weighted-average remaining lease term | 11.9 years | 5.5 years | | Weighted-average discount rate | 6.87% | 7.15% | - The company is leasing a new **70,000 square foot manufacturing facility** in Stevenage, UK, which is being handed over in portions as construction completes. This has contributed to the increase in the remaining lease term[48](index=48&type=chunk) Future Fixed Lease Payments (in thousands) | Period | Amount | | :--- | :--- | | Remainder of 2023 | $4,661 | | 2024 | $5,299 | | 2025 | $3,815 | | 2026 | $3,587 | | 2027 | $3,587 | | Thereafter | $18,464 | | **Total lease payments** | **$39,413** | [Note 12. Commitments and Contingencies](index=14&type=section&id=Note%2012.%20Commitments%20and%20Contingencies) The company has license agreements with potential future milestone and royalty payments, but no milestones were deemed probable as of March 31, 2023, and no litigation was pending - The company has license agreements with UCLB, Noile, and Adaptive that include potential future milestone and royalty payments[57](index=57&type=chunk)[58](index=58&type=chunk)[59](index=59&type=chunk) - As of March 31, 2023, no milestones under these agreements were considered probable of being achieved[59](index=59&type=chunk) - The company was not a party to any litigation and had no contingency reserves as of March 31, 2023[60](index=60&type=chunk) [Note 13. Related parties](index=15&type=section&id=Note%2013.%20Related%20parties) Blackstone and Syncona are identified as related parties due to significant ownership, with several related parties purchasing **$113.0 million** in ADSs during the December 2022 public offering - Blackstone and Syncona Portfolio Limited are considered related parties as they each own **more than 10%** of the Company's outstanding voting securities[62](index=62&type=chunk)[64](index=64&type=chunk) Related Party Purchases in December 2022 Public Offering | Related Party | ADSs Purchased | Total Purchase Price (in millions) | | :--- | :--- | :--- | | Syncona Portfolio Limited | 14,000,000 | $28.0 | | Deep Track Capital, LP | 15,000,000 | $30.0 | | Qatar Investment Authority | 15,000,000 | $30.0 | | Armistice Capital, LLC | 10,000,000 | $20.0 | | Entities affiliated with Blackstone | 2,500,000 | $5.0 | | **Total** | **56,500,000** | **$113.0** | [Note 14. Subsequent Events](index=16&type=section&id=Note%2014.%20Subsequent%20Events) The company evaluated all events through May 4, 2023, and concluded no subsequent events required disclosure in the condensed consolidated financial statements - The Company evaluated subsequent events through May 4, 2023, and concluded that no event has occurred that requires disclosure[67](index=67&type=chunk)

Financial Data and Key Metrics Changes - Cash and cash equivalents at the end of December 2022 totaled $382.8 million, an increase from $310.7 million at the end of December 2021 [37] - Net total operating expenses for 2022 were $168 million, compared to $165 million in 2021 [37] - Net loss attributable to ordinary shareholders was $148.8 million for 2022, compared to $142.1 million for 2021, with a basic and diluted net loss per share of $1.57 compared to $1.97 in the previous year [42] Business Line Data and Key Metrics Changes - Research and development expenses increased by $7.2 million to $142 million in 2022, primarily due to increased clinical and manufacturing costs related to the obe-cel candidate [38] - General and administrative expenses remained consistent at $31.9 million for both 2022 and 2021 [39] - License revenue was $6.2 million in 2022, with potential for additional revenue from recent collaborations [13] Market Data and Key Metrics Changes - The market opportunity in relapsed refractory ALL remains unchanged, with approximately 3,000 patients in need of therapy across the U.S., Europe, and Japan [26] - Blincyto, the standard of care in relapsed refractory ALL, achieved sales of $583 million in 2022, reflecting a year-over-year growth of 24% [27] Company Strategy and Development Direction - The company plans to submit a Biologics License Application (BLA) for obe-cel by the end of 2023, with a commercial launch targeted for 2024 [11][28] - The company is focused on expanding its manufacturing capabilities with the completion of the Nucleus facility, which will support approximately two-thirds of the estimated market demand for adult ALL [15][35] - The company is exploring additional indications for obe-cel beyond ALL, including relapsed refractory non-Hodgkins lymphoma and chronic lymphoblastic leukemia [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the safety profile of obe-cel, which is expected to facilitate its use in community settings [46] - The company anticipates a significant year ahead, with key milestones including regulatory submissions and data presentations planned for mid-2023 [43][44] - Management highlighted the potential for collaborations to enhance the company's pipeline and market position [44] Other Important Information - The company received a total of $70 million in milestones from Blackstone Life Sciences due to positive interim analysis results for obe-cel [12] - The company is preparing for commercialization by establishing awareness and value propositions for payors [29] Q&A Session Summary Question: What is the incidence of grade 3 CRS in the FELIX study? - Management noted that high grade CRS was less than 3% and ICANS was less than 8%, which aligns with current standards in non-academic centers, supporting broader use of the product [46] Question: What data will be included in the BLA submission? - The BLA will focus on demonstrating clinical benefit in patients with morphological disease, including time-dependent outcomes and safety profiles [48][49] Question: What is the scope of the AUTO8 study in multiple myeloma? - The AUTO8 study is a small Phase I clinical study involving around 10 patients, with initial evaluations planned [55] Question: How will obe-cel be positioned in the market? - Obe-cel is expected to be positioned in the relapsed refractory setting, potentially after Blincyto therapy, with plans to evaluate its activity in patients who have received prior treatments [56][72] Question: What are the expectations for the FELIX data? - Management expects the FELIX data to show a similar durability profile to previous studies, although long-term follow-up is required for confirmation [60][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Conference Call Participants Mara Goldstein - Mizuho Matthew Phipps - William Blair James Shin - Wells Fargo Securities Gil Blum - Needham & Company Operator Hello ladies and gentlemen and welcome to the Autolus Therapeutics Third Quarter 2022 Financial Results ...